By rray, 9 February, 2023 Exclude Patient Type Detail Header No Detail Type Text Detail Text Consider healthy lifestyle behaviors DM self mgmt education and support DSMES avoidance of therapeutic inertia and social determinants of health SDOH when choosing glucose lowering tx A Use a person centered shared decision making approach to guide choice of pharmacologic agents Consider effects on CV and renal comorbidities effectiveness hypoglycemia risk impact on wt cost and access risk for adverse reactions and tolerability and indiv Glucose lowering tx plan should consider approaches that support wt mgmt goals A Use pharmacological strategies that provide sufficient effectiveness to achieve and maintain intended tx goals A Don t delay tx modification intensification or deintensification for adults not meeting individualized tx goals A Re evaluate medication plan and medication taking behavior at regular intervals e g q3 6mo and adjust as needed to incorporate specific factors that impact choice of tx E Consider early combo tx at tx initiation to shorten time to attainment of individualized tx goals A In pts w o CV and or kidney dz pharmacologic agents should address both individualized glycemic and wt goals A In pts who haven t achieved their individualized glycemic goals selection of subsequent glucose lowering tx should account for individualized glycemic and wt goals plus presence of other metabolic comorbidities and risk of hypoglycemia A In pts who haven t achieved their individualized weight goals additional wt mgmt interventions e g intensification of lifestyle modifications structured wt mgmt programs pharmacologic agents or metabolic surgery as appropriate are recommended A Patient Type Detail Header (Long) General tx considerations
